← boardnext 2027-06
SVRA
Savara Inc.distress 3/10 · well-funded / low risk$5.55-2%today-20% from 52w high
Lead: Autoimmune Pulmonary Alveolar Proteinosis
Revenue
pre-revenue
Liquidity
$203M
Runway
1.9 yrs
Shares 1y
+19%
Price & events
-14.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
+0.5%
1W
-4.0%
1M
+12.3%
3M
-7.8%
6M
+122.9%
1Y
+24.4%
2Y
+317.3%
5Y
+374.4%
All
Overview
- Market Cap
- $1.14B
- Enterprise Value
- $1.13B
- Volume
- 150.93K
- 52 Week Range
- $2.26 – $6.94
- Total Shares
- 204.93M
- Float Shares
- 130.12M
- Short %
- 18.27%
- % Held by Insiders
- 2.57%
- % Held by Institutions
- 104.42%
- RVOL
- 0.08x
- Beta
- 0.24
Pipeline stages · 1 programs
Molgramostim
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | Molgramostimfast trackbreakthroughorphan | Autoimmune Pulmonary Alveolar Proteinosis | — | recruiting |
Catalyst news & presentations · 5
- 2026-08-13earningsEarningsEarnings releaseyahoo
- by the end of the yearregulatory submissionFiled (NDA/BLA)MOLBREEVI · MAA filing for MOLBREEVI in EuropeSEC 8-K
- fourth quarter of 2025regulatory submissionFiled (NDA/BLA)molgramostim · Resubmit BLA for molgramostimSEC 8-K
- 2025-10-29partnershipMOLBREEVI · Entered into royalty funding agreement with RTW for $75M, contingent on FDA approval.SEC 8-K
- 2025-05-27refuse to filemolgramostim · FDA issued RTF for BLA due to insufficient CMC dataSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-12-23HC Wainwright & Co.Buy
- 2025-12-18Wells FargoOverweight
- 2025-11-14OppenheimerOutperform
- 2025-11-13CitizensMarket Outperform
- 2025-10-23JMP SecuritiesMarket Outperform
- 2025-09-09GuggenheimBuy
Competitors — Autoimmune Pulmonary Alveolar Proteinosis
- none identified
Recent news
- 2026-07-22Here's Why You Should Add Savara Stock to Your Portfolio Now - TradingView
- 2026-07-22Here's Why You Should Add Savara Stock to Your Portfolio Now - Zacks Investment Research
- 2026-07-14Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025 - The National Law Review
- 2026-07-05Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA - TradingView
- 2026-06-26SVRA Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-22Savara CFO David Lowrance sells $2.24m in company stock - Investing.com
- 2026-06-22Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
- 2026-06-22Savara Inc SEC Filing (Jun 22, 2026) - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.